Researchers found that patients with obesity are diagnosed with endometrial cancer (EC) at a significantly younger age across all molecular subgroups, while black women, especially those with obesity, had higher rates of TP53-mutated disease, and prior malignancy history also correlated with specific subgroups, according to a recent study published in the Cancer journal.
EC is the most common gynecological malignancy in Western countries, with a rising incidence due to the obesity epidemic. Causes center on obesity-related mechanisms (elevated estrogens, hyperinsulinemia, inflammation), advanced age and genetic predisposition.
Learn more about EC causes and risk factors
Current treatment is primarily surgical staging followed by risk-adapted adjuvant therapy (chemotherapy/radiotherapy), now increasingly guided by molecular classification per updated ESGO/ESTRO/ESP guidelines, yet the study argues for greater personalization that incorporates macroenvironmental variables.
Current evidence from molecular tumor classification (TCGA subgroups) and large European cohorts shows consistent age-BMI-subgroup interactions and ethnic disparities (e.g., Black women over-represented in TP53-mutated tumors).
“The observed trend for improved survival in TP53-mutated EC in patients with obesity is clinically very relevant, and warrants further prospective and mechanistic investigation,” the authors wrote.
The authors aimed to investigate whether patient macroenvironmental factors, including age, body mass index (BMI)/obesity, comorbidity burden, ethnicity, and history of previous malignancy, significantly influence adherence to the four TCGA molecular subgroups in endometrial cancer, hypothesizing that these patient-level variables are not independent of tumor molecular classification..
The study was a retrospective analysis merging the public TCGA cohort with the European ENITEC cohort into a primary research set with complete surgical staging, BMI, age, and molecular data.
Key outcomes confirmed higher age at diagnosis in TP53-mutated cases, younger diagnosis in obese patients across all subgroups, improved survival in obese TP53-mutated patients (differences lost at BMI>35), and ethnicity/comorbidity associations.
“This study demonstrates that patient-related factors are of undiminished importance and their integration with molecular factors is essential,” the authors concluded.
Sign up here to get the latest news, perspectives, and information about EC sent directly to your inbox. Registration is free and only takes a minute.
